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Abstract
RUNX gene over-expression inhibits growth of primary cells but transforms cells
with tumor suppressor defects, consistent with reported associations with tumor
progression. In contrast, chromosomal translocations involving RUNX1 are
detectable in utero, suggesting an initiating role in leukemias. How do cells
expressing RUNX1 fusion oncoproteins evade RUNX-mediated growth suppres-
sion? Previous studies showed that the TEL-RUNX1 fusion from t(12;21) B-ALLs is
unable to induce senescence-like growth arrest (SLGA) in primary fibroblasts while
potent activity is displayed by the RUNX1-ETO fusion found in t(8;21) AMLs. We
now show that SLGA potential is suppressed in TEL-RUNX1 but reactivated by
deletion of the TELHLHdomain ormutation of a key residue (K99R). Attenuation of
SLGA activity is also a feature of RUNX1-ETO9a, a minor product of t(8;21)
translocations with increased leukemogenicity. Finally, while RUNX1-ETO induces
SLGA it also drives a potent senescence-associated secretory phenotype (SASP), and
promotes the immortalization of rare cells that escape SLGA.Moreover, theRUNX1-
ETOSASP is not strictly linked to growth arrest as it is largely suppressed byRUNX1
and partially activated by RUNX1-ETO9a. These findings underline the heteroge-
neous nature of premature senescence and the multiple mechanisms by which this
failsafe process is subverted in cells expressing RUNX1 oncoproteins.
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1 | INTRODUCTION
The phenomenon of oncogene-induced-senescence (OIS)
was first described in primary murine fibroblasts expressing
oncogenic Ras1 and despite early scepticism was firmly
established as a physiologically relevant failsafe mechanism
that protects against cancer development.2–5 More recently it
has become clear that oncogene-induced senescence is just
one facet of cellular senescence that may result from a variety
of stimuli that include DNA damage, tumor suppressor
activation and epigenetic perturbation. While the positive
outcomes of cellular senescence include tumor suppression
and tissue repair, it may also lead to age-related degeneration
and tumor progression (reviewed in ref.6). The latter response
appears to be associated with the senescence-associated
secretory phenotype (SASP) a phenomenon that results from
release of an array of cytokines and other agonists with
proinflammatory and/or pro-oncogenic activities.7
Primary fibroblasts have provided an informative system
to study the role of individual genetic lesions in these
processes, as unlike cancer cell lines these cells are at an early
developmental stage, retain normal karyotypes and display a
finite lifespan.8 Over-expression of any of the three RUNX
genes induces a potent senescence-like growth arrest (SLGA)
in primary fibroblasts but by a more immediate mechanism
than Ras OIS, which manifests as a response to hyper-
proliferation and DNA damage signaling.9,10 The wider
relevance of these observations in primary fibroblasts is
underlined by the growth suppressive effects of RUNX in
human CD34+ cells and murine stem and progenitor cells, B
cells and foetal thymocytes.11–13 Crucially, primary fibro-
blasts lacking functional Arf/p53 fail to undergo RUNX
SLGA and become tumorigenic,9 recapitulating the in vivo
collaboration of Runx over-expression and p53 deficiency in
lymphomagenesis14 and illuminating the action of RUNX
genes as “conditional oncogenes” that require collaborating
genes to reveal their latent oncogenic potential.15 Moreover,
RUNX functions appear to be necessary for Ras OIS, as
indicated by the failure of senescence and oncogenic
transformation of Runx2-deficient murine fibroblasts.10
RUNX1 is one of the most frequently involved genes in
human leukemiawhere it is subject to a range of chromosomal
translocations, loss of function mutations and copy number
gains, while all three murine Runx genes act as targets for
transcriptional activation by insertional mutagenesis in
lymphoma models, highlighting the dualistic potential of
RUNX factors to act as oncogenes or tumor suppressors
according to context.16 The archetypal chromosomal fusions
involving RUNX1 are the t(8;21) translocation which results
in C-terminal truncation of RUNX1 and fusion to ETO in
acute myeloid leukemia and the t(12;21) translocation which
fuses an almost complete RUNX1 isoform at its N-terminus to
a truncated TEL/ETV6 moiety in childhood B-ALL.17
Notably, these translocations appear as early events in
leukemogenesis that often arise in utero, as indicated by their
detection in neonatal blood spots.18,19 Latency periods to
detectable disease can be protracted, supporting the existence
of long lived or stable parental clones requiring collaborating
secondary mutations for leukemic progression.18,20 Further
evidence that RUNX1 is not a typical tumor suppressor is
provided by the observations that leukemia cells require
normal RUNX1 expressed from the unaffected allele for
viability,21 while progressing t(12;21) leukemias show
sustained high level expression of RUNX1 and frequent
copy number gains of chromosome 21.22,23
The consequences of oncogenic fusions for SLGA
potential are enigmatic, as the TEL-RUNX1 (TR) fusion
appears to have lost this activity despite retention of an almost
full-length RUNX1 moiety, while the RUNX1-ETO fusion
(RE) that carries a C-terminally truncated RUNX1, induces
intense SLGA in primary fibroblasts and haematopoietic
progenitor cells.24,25 However, SLGA induced by RUNX1
and RUNX1-ETO are mechanistically distinct, as they
display distinct morphological features and while both
require intact p53, only RUNX1-ETO is able to induce
SLGA in p16CDKNA2 deficient fibroblasts.24 In this study we
show that attenuation of senescence activity is also a feature
of RUNX1-ETO9a, a splice variant of RUNX1-ETO with
markedly increased leukemogenicity in mouse models.26 The
paradoxical strong induction of SLGA by RUNX1-ETO
appears to be counterbalanced by a prolific SASP response
and an ability to promote immortalization and outgrowth of
cells that escape from SLGA. Our findings demonstrate
multiple mechanisms by which transformed cells escape from
RUNX growth suppression and provide a rationale for the
contrasting secondary collaborating mutations required for
TEL-RUNX1 and RUNX1-ETO associated leukemias.
2 | MATERIALS AND METHODS
2.1 | Cells and viral vectors
Hs68 human foreskin fibroblasts (Sigma-Aldrich, Gillingham,
UK), primarymurine embryonic fibroblasts (MEFs—prepared
in house9) and 293T cells (ATCC) were maintained in DMEM
(Invitrogen, Paisley, UK) supplemented with 10% foetal calf
serum (FCS), 2 mM L-glutamine and 100 units each of
penicillin and streptomycin.REH lymphocytic leukaemia cells
(ATCC) and EBV-transformed lymphoblastoid cell line,
LCL114 (a kind gift from Professor Ruth Jarrett) were
maintained inRPMI1640 (Invitrogen) supplemented as above.
Lentiviral vectors were based on the pLenti6 plasmid
(Addgene, Teddington,UK) carrying the puromycin selectable
marker. The RUNX1 constructs contain a 1.6 kb EcoR1
fragment encoding either RUNX1P1 or P2; P1 is the control
isoform forTRexperiments, P2 for those comparingRE/RE9a.
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RE is a 2.2 kb Xba1 fragment and TR is a 2.5 kb EcoR1
fragment all excised from the corresponding pBabe-PURO
retroviral construct24 and subcloned into the polylinker region
of pLenti-PURO. RE9a is a 1.9 kb fragment amplified from
MIPAE9a (Akindgift fromProfessorD.E. Zhang,TheScripps
Research Institute, La Jolla, Ca.) using EcoR1 tagged forward
(5′-CGAGAATTCTCGAGGTTGATCTCTCGAGG) and re-
verse (5′- CGGAATTCGTTAATTCACTAGTGATTCCAT
CG) primers and subcloned as above. TRΔHLH was excised
on an EcoR1-Not1 fragment from pMSCV TRΔHLH-IRES-
GFP (a kind gift from Prof. O. Williams, UCL, London). The
overhanging 5′ ends (Not1/pMSCV and Sal1/pBabe-PURO)
were blunt ended using a Klenow Fill-in Kit (Agilent
Technolgies, Stockport, UK) according to the manufacturer's
protocol before sequential EcoR1 digestion and ligation.
TRK99R was generated from pBabeTR24 by site-directed
mutagenesis using the QuikChange II Site-Directed Mutagen-
esis Kit (Agilent Technologies) according to the manufac-
turer's instructions. The mutant strand synthesis reaction was
performed on 5-50 ng template DNA and 125pMol of primer
pairs TRK99Rf (5′-CTGCTGCTGACCAGAGAGGACTTT
CGC) AND TRK99Rr (5′-GCGAAAGTCCTCTCTGGTCA
GCAGCAG-).
2.2 | Lentivirus transduction
293T cells were plated at 1.1 × 107 in T150 flasks and
incubated overnight at 37°C. Transfections were carried out
according to the manufacturer's instructions for adherent cells
using Lipofectamine 2000 (Invitrogen). 8 μg psPAX2
and 5 μg pCMV-VSVG helper plasmids (kindly gifted by
Dr J. van Tuyn, Beatson Institute, Glasgow) were transfected
with 20 μg of each pLenti-PURO construct. Viral super-
natants were harvested after 48 and 72 h incubations at 37°C,
filtered through 0.45 μm filters (Sartorius, Epsom, UK) and
concentrated by ultra centifugation for 2 h at 166 880g.
Supernatants were frozen in aliquots at −80°C. Hs68
fibroblasts were plated at 8 × 105 in 10 cm dishes and
incubated overnight before infection at a multiplicity of
infection (MOI) of 1 for 12-16 h in the presence of 4 μg/mL
polybrene (Sigma). Selection was performed using 2 μg/mL
puromycin for 4 days. Control uninfected Hs68 fibroblasts
died under these selection conditions. Following selection
Hs68s were removed from the culture dish, counted for viable
cells and used for experimental analysis.
2.3 | Lentiviral titration
NIH 3T3 cells were seeded at 8 × 103 per well in 12-well plates,
incubated overnight, then the cells were fedwith 1mL complete
media supplemented with polybrene (4 µg/mL). Virus was
thawed rapidly at 37°C and agitated to resuspend particles.
11 µL of virus stock were added to one well andmixed. A series
of 1:5 serial dilutions were performed over six wells and plates
were incubated for 48 h at 37°C. The virus/polybrene mixture
was replaced with complete media supplemented with 2 µg/mL
puromycin (Sigma) and incubated for 8 days. Cells were fixed
with 100%methanol for 10min then washedwith PBS (pH 6.8)
and stained with 10% Giemsa in PBS (pH 6.8) for 30min. The
plates were washed with water and discreet colonies counted.
Plaque-forming units (pfu)/µL was calculated.
2.4 | Growth curves, senescence staining, and
3T3 passage culture
Cells were plated at 2.5 × 104/well in 12-well plates in
selection medium containing 2 μg/mL puromycin. Live cell
counts were carried out in triplicate using a haemocytometer
and trypan blue as a vital stain.Media were changed every 3-4
days. Senescence staining was assayed using a solution of
X-gal (Invitrogen) at pH 6.0 to detect SA-β-galactosidase
activity as described.9 3T3 passage culture was essentially
performed according to the protocol of Todaro and Green.27
2.5 | Analysis of intracellular reactive oxygen
species (ROS)
To assess the generation of intracellular ROS, transduced
cells were plated after puromycin selection in a six-well dish
at 3 × 105 per well. After 6 days the cells were washed in PBS
and then incubated in the dark for 20 mins at 37°Cwith 15 μM
2′, 7′-dichlorofluorescein diacetate (DCF-DA, Millipore,
Watford, UK) before harvesting according to the manufac-
turer's instructions. DCF fluorescence (maximum excitation
495 nm; maximum emission 530 nm) was quantitated on an
Accuri C6 flow cytometer (BD Biosciences, Oxford, UK)
using a 488 nm blue laser and detecting fluorescence on the
FL1 channel with a 533/30 filter. The cell population was
gated on a forward scatter/side scatter plot to exclude debris.
Significance values were determined by Student's t-test. ROS
scavenging was achieved by treating cells with sodium
pyruvate (NaPyr). Sodium pyruvate was diluted in ddH2O
and added to cell culture medium at 250 µM. Treatment of
cells commenced on the day of antibiotic selection and
medium was changed every 2-3 days.
2.6 | Human cytokine array
Cells were cultured at 2.5 × 104 per well in 12-well plates for
4 days before replacing the medium with low serum media
(0.2% FCS) for a further 48 h. The conditioned media was
harvested and diluted to control for cell number before
application to a human cytokine array chip (RayBiotech,
Norcross, GA). Chips were treated as specified in the
manufacturer's guidelines. Chips were sent for data extraction
and analysis (RayBiotech) where ODs were measured. OD
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values were normalised to background levels determined
from the empty vector pLenti-PURO, control cells.
2.7 | IL-6 ELISA
Cells were plated out at 2.5 × 104 in 12-well plates and fed
with fresh media every 3 days. On day 6 post-selection, the
cell culture medium was harvested and stored at
−80°C and the cells were counted. Harvested media was
thawed rapidly at 37°C. A Quantikine IL-6 ELISA (R&D
Systems, Abingdon, UK) was performed in accordance
with the manufacturer's protocol. Plates were analyzed at
450 nm using an ELISA plate reader. Plates were
additionally read at 540 nm to remove background
fluorescence. The values were normalized to cell count
and final values were normalized to the empty vector
control.
2.8 | Protein extraction and Western blotting
Preparation of whole cell protein extracts was performed as
described previously using 0.4% Triton,9 0.5% NP40,28 0.1%
SDS (RIPA) or 1.0% SDS (RIPA) lysis buffer supplemented
with 0.1 μg/mL okadaic acid (OA), 5 μg/mL aprotinin, 5 μg/
mL leupeptin, 5 μg/mL pepstatin A, 1 mM benzamidine, and
50 μg/mL PMSF).
Samples equivalent to 20-30 μg protein (Bio-Rad
protein concentration assay, Bio-Rad Laboratories, Wat-
ford, UK) were resolved on SDS-polyacrylamide gels or
Novex gradient gels and electro-blotted onto Hybond-ECL
nitrocellulose membranes (GE Healthcare, Little Chalfont,
UK). Proteins were visualized using the following primary
antibodies: RUNX (Caltag Medsystems, Little Balmer, UK,
D207-3), p16INK4A, p53, actin (Santa Cruz Biotechnology,
Heidelberg, Germany, sc-468, sc-126, and sc-1616),
Calnexin and p19ARF (Abcam, Cambridge, UK, ab22595
and ab80), p38MAPK and phospho-p38MAPK (Cell Signalling
Technologies, Leiden, The Netherlands, 9212 and 9211).
Western blots were developed with ECL (Thermofisher
Scientific, Paisley, UK) according to the manufacturer's
guidelines.
2.9 | Statistical analysis
Graphs were plotted and statistics calculated using GraphPad
Prism (GraphPad Software, Inc., La Jolla, CA). Error bars
relate to standard deviations. All statistical comparisons were
performed using the Student's t-test. Unless stated a
significance value ≤0.05 is denoted by (*), ≤0.01 by (**),
and ≤0.001 by (***). Growth curves and bar charts show one
representative experiment of three, each performed on
triplicate samples, unless otherwise stated.
3 | RESULTS
3.1 | Suppression of senescence-like growth
arrest by TR requires an intact HLH domain
and is abolished by K99R mutation
We showed previously that the TR fusion oncoprotein does
not induce SLGA in primary fibroblasts despite its retention
of an almost full-length RUNX1 protein moiety.24 The most
likely explanation for this phenomenon appeared to be a
dominant suppressive effect arising fromN-terminal fusion to
a TEL sequence. To test this hypothesis we examined the
effect ofmutating TEL functional domains in TR (Figure 1A).
Previous studies showed that the TEL helix-loop-helix (HLH)
domain, also known as the pointed domain, is required for
homotypic dimerization29 and is also important for the
leukemogenic activity of TR in haematopoietic stem cell
models of B-cell ALL.30 We tested the ability of a deletion
mutant (TRΔHLH) to induce SLGA in Hs68 primary human
fibroblasts. RUNX1 and TR were included as positive and
negative controls respectively. Ectopic expression of
TRΔHLH was readily detectable in fibroblasts (Figure 1B),
and induced a rapid and dramatic growth arrest that was
morphologically indistinguishable fromRUNX1 (Figure 1C),
accompanied by an intense pattern of SA-βGal staining
activity (Figure 1D). Consistent with our previous findings,
Hs68 cells expressing TR retained a fibroblastic morphology
and continued to divide at comparable rates to pLentiPURO
control cultures. The HLH domain is required for nuclear
localization of TEL, while within this domain lysine 99 has
been reported as a site that is required for recruitment of the
TR fusion protein to TEL nuclear bodies.31 We therefore
tested the effect of K99R substitution on SLGA potential by
introducing this mutation into our expression construct. Like
the TRΔHLH mutant, TRK99R induced profound growth
arrest and SA-βgal staining (Figures 1C and 1D).
Similar results were observed in primary murine
embryonic fibroblasts (MEFs) where RUNX1 and TRK99R
induced a profound growth arrest while TR cells grew, albeit
more slowly than vector transduced control cells (Figure 2A).
Analysis of senescence-associated markers in these cells
(Figure 2B) showed that the K99R mutation reactivates the
induction of p19Arf/p53 signalling as well as p16CDKN2A. By
contrast, TR had no effect on these senescence markers
indicating that it acts neither as an inducer nor as a dominant
negative repressor of these failsafe responses.
3.2 | End stage leukemia cells are refractory to
growth arrest by TRK99R
RUNX1 strongly induces expression of p16CDKN2A and our
previous studies showed that RUNX1 SLGA fails in Leiden
human fibroblasts that lack expression of p16CDKN2A due to a
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homozygous mutation that does not affect the p14ARF reading
frame.24,32 Notably, p16CDKN2A expression can also be lost in
t(12;21) leukemias due to gene deletion33 or promoter
hypermethylation in ALL34 and gene deletion has been
detected in the prototypic REH cell line.35 It was therefore
interesting to test the resistance of REH cells to ectopic
RUNX1. However, high basal levels of RUNX1 expression
obscure measurement of ectopic RUNX1 expression in these
cells. For this reason we used the more readily detectable
TRK99R as a surrogate inducer of SLGA. As shown in
Figure 2C, ectopic expression of TRK99R was detectable by
Western blot analysis of REH cells and an EBV-immortalized
lymphoblastoid cell line which served as a control line with
intact p16CDKN2A expression. Notably, only the LCL line was
susceptible to growth arrest while REH tolerated TRK99R
expressionwithout any obvious phenotypic effect (Figure 2D).
3.3 | Senescence-like-growth-arrest is
attenuated in RE9a, a leukemogenic variant
isoform of RUNX1-ETO
In contrast to TR, the RUNX1-ETO (RE) fusion which is
found in many cases of AML induces a potent SLGA in
primary human foreskin fibroblasts.24 However, the t(8;21)
fusion also generates a minor spliced variant of RE lacking
two C-terminal ETO repressor domains that is much more
potently leukemogenic in mouse models26 (Figure 3A). To
determine whether the increased leukemogenic potential of
RE9a is associated with attenuation of SLGA, we introduced
RE and RE9a into primary human foreskin fibroblasts (Hs68)
and examined the cells for markers of this anti-cancer failsafe
mechanism. Ectopic expression levels of RE9a were greater
than for RE (Figure 3B) but failed to induce a flattened
morphology or perinuclear SA-βGal staining typical of RE-
expressing cells (Figure 3C). Moreover the Hs68 cultures
continued to proliferate with comparable kinetics to the vector
controls indicating that cell growth was refractory to RE9a
expression (Figure 3D).
As reported, RUNX1-ETO SLGA is associated with
accumulation of intracellular ROS and p38MAPK phosphor-
ylation in primary human fibroblasts.24 To assess the capacity of
RE9a to induce these responses we transduced Hs68 fibroblasts
with RE, RE9a, and the empty vector control (pLenti-puro) and
treated at the point of puromycin selection with sodium
pyruvate to scavenge for intracellular ROS. Six days after re-
plating when visible signs of senescence were apparent, ROS
were quantitated by FACS-based detection of emissions from
the peroxide-sensitive fluorophore DCF-DA. As shown in
Figure 4A,REwas confirmedas an inducer of intracellularROS
which failed to accumulate abovebackground levels in response
to RUNX1 or RE9a. Moreover scavenging in the presence of
sodium pyruvate reduced detectable ROS for all cultures but
wasmost striking for REwhere background levels of ROSwere
restored (Figure 4B). Restoration of ROS levels was accompa-
nied by morphological reversion and normal proliferation for
RE, but had no effect on RE9a cultures (Figures 4C and 4D).
FIGURE 1 Deletion or mutation of the TEL domain reactivates SLGA activity in the TR fusion oncoprotein. Hs68 cells were transduced
with lentivirus vectors encoding RUNX1, TR, TRΔHLH, TRK99R or the empty vector (PURO) control. (A) Schematic of TR and the HLH
mutants, TRΔHLH & TRK99R. (B) Western blot analysis of RUNX1, TR, TRΔHLH and TRK99R expression in transduced Hs68 cells probed
for RUNX. (C) Representative growth curves of transduced Hs68 cells performed over a 9 day period. (D) Images captured after staining cells
for SA-β-Gal activity at pH6.0, 6 days post-selection when signs of senescence were apparent
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To determine the consequences of successful scavenging
for p38MAPK activation, we analyzed expression levels of
phospho-p38MAPK by Western blotting in the presence and
absence of sodium pyruvate. As shown in Figure 4E induction
of phospho-p38MAPK was unique to RE-expressing cells
and completely abolished in the presence of sodium pyruvate.
Together these data indicate a requirement for intracellular
ROS for activation of p38MAPK and SLGA in response to
RE. Moreover it appears likely that the failure of RE9a to
induce SLGA reflects loss of function or reduced engagement
of ROS/p38MAPK signalling pathways.
The induction by RE of ROS, a potentially tumor
promoting response,36 suggested to us that the unique SLGA
associated with RE might have pro-oncogenic features. We
therefore examined senescent cells for release of IL-6, amajor
component of the senescence-associated secretory pheno-
type.6 As shown in Figure 4F, supernatant from Hs68 cells
transduced with RUNX1, RE, or RE9a were tested for the
presence of IL-6 six days after selection by ELISA. This
analysis showed greater than fourfold increase in IL-6 release
from RE-expressing cells. RUNX1-transduced cells showed
no significant increase, while RE9a cells showed a partial
response, despite the lack of growth arrest and morphological
changes associated with SLGA in these cells.
3.4 | RE induces a uniquely potent senescence-
associated secretory phenotype
Our findings suggested that the RE-associated SASP is at
least partly dissociable from growth arrest as IL-6 is not
induced in senescent cells expressing RUNX1, but is
significantly induced by RE9a expressing Hs68 cells
which display normal morphology and growth rates. To
test this hypothesis further we analyzed conditioned
media using arrays containing antibodies against 120
secreted proteins (Raybiotech). OD values were adjusted
to exclude background fluorescence and normalized to
the empty vector pLenti-puro control. The full dataset is
listed in Table S1. For presentation in Figure 5A, the top
100 altered SASP components were sorted on the values
obtained from the RE array, with yellow indicating up-
regulation, blue down-regulation, and gray the basal
levels of secretion (equivalent to control). Conditioned
media from RE-expressing cells displayed a robust SASP
with the majority of secretory markers up-regulated
relative to the empty vector control (P = 7.4 E-6; students
t-test). In contrast RUNX1 displayed a largely repressive
profile (P = 5.4 E-30) suggesting that senescence secre-
tion is not a major contributor to RUNX1-induced SLGA.
FIGURE 2 Reactivation of failsafe pathways induced by the mutated TR fusion protein reveals roles of p53 and p16CDKN2A in RUNX1 SLGA.
Primary MEFs were transduced with retroviral vectors encoding RUNX1, TR, TRK99R or the empty vector (PURO) control. (A) Growth curves on
MEF cells expressing RUNX1, TR, TRK99R or Puro empty vector control. Mean viable cell counts were plotted over the course of 12 days. (B)
Western blot analysis showing relative levels of p19, p16CDKN2A and p53 in response to TR at d13. (C left panel) EBV-immortalised human B cells
(LCL114) and REH cells were transduced with lentiviral vectors expressing TRK99R (+) or the pLenti-Puro empty vector control (−). TRK99R
expression levels analysed by western blotting in both cell types. (C right panel) Western blot analysis of p16INK4A expression levels in the LCL114
and REH cells. (C) Representative growth curves of the LCL114 and REH transduced with TRK99R or Puro over 7 days
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RE9a generated an intermediate SASP profile despite the
normal growth appearance of Hs68 cells expressing
RE9a. As further illustrations of the contrasting effects of
RE and RUNX1, the box-whisker plot in Figure 5B shows
the most significantly changed SASP components for RE
(n = 87), which are largely repressed by RUNX1, and
display heterogeneous responses to RE9a. Also, the most
strongly up-regulated exemplars from the RE SASP are
shown in Figure 5C where again it is clear that most are
either repressed or minimally induced by RUNX1.
Notably, the top 3 RE SASP components (in red typeset)
are cytokines with annotated pro-oncogenic functions
(CCL5, CCL2, and CXCL1).37–39 These observations
suggest that the RE and RUNX1 SASP responses are
likely to have divergent paracrine effects on bystander
cells.
3.5 | RE but not RUNX1 allows escape from
senescence and promotes immortalization of
primary murine fibroblasts
The finding that RE induces a robust and potentially
pro-oncogenic SASP led us to consider whether its
potent growth suppression might be reversed in some
circumstances. We examined prolonged expression of RE in
primary MEFs which are prone to early growth arrest under
normoxic conditions but can proliferate and often undergo
spontaneous immortalization when grown upon 3T3
passage culture27 in low oxygen tension. As previously
reported9,24 introduction of RE or RUNX1 into primary
MEFs was accompanied by a profound growth arrest
(Figure 6A) and flattened morphology (Figure 6B) typical
of senescent cells. RE9a displayed an attenuated senescent
phenotype in these cells, with some areas of flattened cells
but also foci of fibroblastic cells that rapidly expanded
within the cultures (Figures 6A and 6B). Consistent with
their persistent growth, cells expressing RE9a underwent
spontaneous immortalization after approximately 6-7 pas-
sages (Figure 6C). More surprising was the spontaneous but
slightly delayed immortalization of MEFs expressing RE
after approximately 8-9 passages. Rapid outgrowth was
observed in 4 out of 4 MEF cultures, which overtook vector
control cells in cumulative cell counts. In contrast, RUNX1-
expressing cells failed to expand with serial passage. These
findings further illustrate the contrast between SLGA
induced by RUNX1 and RE and suggest a link between
the SASP and the ability of RE cells to escape from
senescence.
FIGURE 3 RE9a displays markedly attenuated SLGA in primary human fibroblasts. Hs68 cells were transduced with lentiviral vectors
encoding RE, RE9a or the empty vector (PURO) control. (A) Schematic of the RE9a spliced variant compared to RE. (B) Western blot analysis
of RE and RE9a expression in transduced Hs68 cells probed for RUNX. (C) Images captured after staining cells for SA-β-Gal activity at pH6.0,
6 days post-selection when signs of senescence were apparent. (D) Representative growth curves of transduced Hs68 cells performed over a
6 day period
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4 | DISCUSSION
This study elucidates the ability of cells expressing RUNX1
fusion oncoproteins to evade RUNX growth suppressive
potential and supports the predictive value of insights from
primary cell systems for the in vivo behavior of mutant cancer
genes. In two out of three cases (TR, RE9a), RUNX1 SLGA
activity is lost or markedly attenuated in the oncoprotein
derivates, while in the case of RE it appears to be
compensated by a pro-oncogenic secretory response that is
associated with escape from senescence and immortalization.
We have shown that RUNX1 SLGA is masked in the TR
oncoprotein by fusion to the TEL domain and can be
reactivated by deletion of the TELHLH domain or by a single
mutation in the HLH domain of lysine 99 to arginine.
Notably, this mutation has been reported to induce a shift in
protein localization and affects a reported site of post-
translational modification. Sumoylation of the corresponding
site in TEL has been observed,31,40 although there are
multiple alternative post-translational modifiers that target
exposed lysine residues that may also be relevant.41
Unequivocal identification of enzymes responsible for
modifying this site may offer a route to selective killing of
TR-expressing cells in vivo, even if late stage leukemic cells
are predicted to become refractory.
Using TRK99R as a readily detected surrogate for RUNX1
SLGA, we showed that the prototypic t(12;21) cell line REH
is refractory, while primary fibroblasts and a primary
FIGURE 4 Attenuation of ROS production, MAPK signalling and IL-6 production in RE9a-expressing human fibroblasts compared to RE.
Hs68 cells were transduced with lentiviral vectors encoding RE, RE9a or the empty vector (PURO) control and treated at the point of selection
with NaPyr. (A) Intracellular ROS levels in response to NaPyr analyzed 6 days after puromycin selection by flow cytometry-based detection of
DCF-DA fluorescence. The data shown are representative of three independent biological replicates. (B) Mean fluorescence for the experiment
shown in A was quantified and normalized to the empty vector (PURO) control and the data plotted as a bar chart. (C) Images captured after
staining cells for SA-β-Gal activity at pH6.0 on the indicated cell populations grown in the presence and absence of NaPyr for 6 days when signs
of senescence were apparent. (D) Representative growth curves of the same cell populations performed over a 10 day period under the same
conditions. (E) Western blot analysis of phospho-p38MAPK, p38MAPK, and p16CDKN2A expression in the indicated cell populations grown in
the presence and absence of NaPyr for 6 days. (F) Supernatant collected from cells 6 days post-selection was subjected to ELISA for IL-6. Bar
chart shows fold change in IL-6 concentration ± SD compared with PURO control
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B-lymphoblastoid cell line are sensitive. We have shown
previously that RUNX1-mediated SLGA requires integrity of
the CDKN2A locus in human fibroblasts.24 TRK99R induces
p16CDKN2A expression in primary fibroblasts and induces
growth arrest in primary EBV-immortalized lymphocytes that
retain functional p16CDKN2A but not in t(12;21) REH leukemia
cells that fail to express this protein due to gene deletion
affecting both alleles of the CDKN2A locus.42 These
observations provide a rationale for the observation that late
stage t(12;21) cells express high levels of RUNX1 from the
untranslocated allele22 and display frequent acquisition of
extra copies of chromosome 21 in progressing leukemias.23
A significant proportion of t(12;21) leukemias also
display loss of p16CDKN2A due to deletion mutations23,43
and/or hypermethylation.44Moreover, as RUNX1 SLGA also
requires an intact p53 pathway24 it is conceivable that some
t(12;21) leukemias acquire resistance to RUNX1 SLGA by
mechanisms other than loss of p16CDKN2A. In further support
FIGURE 5 RE induces a uniquely potent SASP in human fibroblasts. (A) Supernatant collected from transduced Hs68 cells 6 days post
selection was tested on a human cytokine array to measure SASP induction by RUNX1, RE, and RE9a. Yellow indicates up-regulation relative
to the PURO control while blue indicates down-regulation, while gray is neutral. (B) The relative levels of all SASP components released by
cells expressing RUNX1, RE, and RE9a are depicted as box-whisker plots. The boxplot shows the distribution of cytokine expression, with the
box representing the 1st to 3rd quantiles (Q1-Q3) and the midline representing the median. Whiskers represent either the most extreme data point
or 1.5× the Q1-Q3 interquartile range, whichever is smaller. (C) The fold change in expression in RE (blue bars) and RUNX1 (green bars) of the
20 SASP components most up-regulated in RE (relative to the Puro control). The gray shaded area depicts the baseline. Red text indicates
selected cytokines with a pro-oncogenic effect
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of the importance of both the p53 and Rb arms of the tumor
suppressor response in vivo, the weak oncogenicity of TR in
mice is facilitated in Cdkn2a/Arf deficient cells.45
At the outset of this study, RE presented a paradox as it
retains the ability to induce a potent SLGA in fibroblasts.24 This
observation ran counter to the hypothesis that RE may function
as an oncogene by blocking RUNX1-driven failsafe devices
through transcriptional repression of p14Arf expression.46 In
contrast, we showed that RE induces a potent p53-dependent
SLGA in human primary fibroblasts that lack detectable p14Arf
expression, indicating that RE activates p53 by an alternative
pathway, with the induction of ROS and MAPK signalling as
essential players.Moreover, RE induces p16CDKN2A expression,
albeit more weakly than RUNX1.24 The notion that RE is
oncogenic as a result of transcriptional repression of failsafe
pathways is not tenable in light of these observations.
More recent studies have revealed that cellular senescence
is not necessarily tumor protective. In the SASP response,
senescent cells may release factors that influence bystander
cells in a manner that promotes tumor development.6
Cytokine release may be beneficial through attraction of
immune effector cells and this potential has been explored in
clinical trials of cytokine-based therapies.47 However, the
other side of the coin is that the SASP includes pro-oncogenic
factors and it is notable that cytokines with an annotated pro-
oncogenic role are among the most prominent in the RE
SASP. The ability of RE to promote escape from senescence
and immortalization in primary murine fibroblasts is a further
indication that RE SLGA is not irreversible, and strongly
implicates the SASP in the escape process. Our findings in
primary fibroblasts mirror previous studies in CD34+ cells
where RE expressing cells displayed an early growth
FIGURE 6 RE and RE9a but not RUNX1 promote the immortalization and outgrowth of primary murine fibroblasts. Primary MEFs were
transduced with retroviral vectors encoding RUNX1, RE, RE9a, or the empty vector (PURO) control. (A) Representative growth curves of
transduced cells performed over a 9 day period. (B) Images captured after staining cells for SA-β-Gal activity at pH6.0, 6 days post-selection
when signs of senescence were apparent. (C) 3T3 passage cultures on four independent primary MEF cultures expressing RUNX1, RE or RE9a.
Mean cumulative cell counts were plotted over the course of 14 passages. RUNX1 cultures could not be split beyond passage 8 due to
senescence
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suppression followed by increased self-renewal, while the
surviving cells displayed down-regulation of DNA repair
genes.48,49 It would interesting in future to test whether a
similar RE SASP is expressed in this context.
It is also interesting to note that the RE SLGA is
markedly attenuated in RE9a, a spliced variant of RE that
displays significantly enhanced leukemogenic potency in
retroviral transduction/transplantation mouse models com-
pared to the full-length RE product.26 The difference was
most marked in Hs68 cells where, unlike RE, RE9a induced
no obvious morphological change and failed to induce ROS
or other markers of senescence. Despite this lack of obvious
phenotype, RE9a generates a partial SASP response that
may contribute to its ability to promote MEF growth and
immortalization and, by extrapolation, its leukemogenicity
in vivo. It is important to note, however, that RE9a is not
expressed in isolation in t(8;21) leukemia cells, but
alongside RE and the unmutated RUNX1 allele, and
all three are likely to contribute to regulation of the
SASP in vivo.
This study re-emphasises the heterogeneity of SLGA,
despite the common features of growth arrest, flattened
morphology, and SA-β-gal staining. Subtle differences
between RE and RUNX1 SLGA were already evident
from morphology and the greater tendency of growth
arrested Hs68 cells expressing RE to accumulate in G2.24
This study reveals an even more striking difference, as
RE induces a complex SASP but RUNX1 either fails to
induce or even suppresses production of many of the
same mediators. A similar phenomenon was observed for
the cell cycle regulator p16CDKN2A which has also been
reported to induce senescence without a SASP re-
sponse.50 As p16CDKN2A is both strongly induced by
RUNX1 and essential for RUNX1 SLGA24 a potential
causal link must be considered. Also, from its limited
SASP, it may be predicted that ectopic RUNX1 will not
trigger extensive inflammatory or innate immune re-
sponses in vivo.
The contrasting routes of escape from SLGA in the TR
and RE fusions also shed light on the collaborating mutations
that are selected in the development and progression of
t(12;21) and t(8;21) leukemias. Over 40% of t(12;21)
leukemias carry deletions in genes affecting B-lineage
maturation as well as G1/S cell cycle progression checkpoint
genes such as CDKN2A,51 while in t(8;21) leukemias drivers
of proliferation predominate, with more than 50% of tumors
harboring KIT, NRAS, KRAS, FLT3-ITD, TKD, CBL, or
JAK2 mutations.52 Finally, as leukemia and lymphoma cells
display resistance to RUNX SLGA, and may even become
addicted to RUNX,13,21,53 it is possible that drugs directly
targeting RUNX-CBFB functions may have a role to play in
future therapeutic strategies.54
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